{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:12:09Z","timestamp":1792800729848,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["24K10784"],"award-info":[{"award-number":["24K10784"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015377","name":"Nihon Medi-Physics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015377","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seikeikai"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-026-07860-z","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:44:07Z","timestamp":1774482247000},"page":"4708-4717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Head-to-head comparison of 11C-PiB and 18F-flutemetamol PET in transthyretin cardiac amyloidosis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0989-8369","authenticated-orcid":false,"given":"Takashi","family":"Norikane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamamoto","family":"Yuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukage","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Murao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Mitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"7860_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsj\u00f6 L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213\u201320. https:\/\/doi.org\/10.2967\/jnumed.111.102053.","journal-title":"J Nucl Med"},{"key":"7860_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","volume":"75","author":"SP Lee","year":"2020","unstructured":"Lee SP, Suh HY, Park S, Oh S, Kwak SG, Kim HM, et al. Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis. J Am Coll Cardiol. 2020;75:380\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.037.","journal-title":"J Am Coll Cardiol"},{"key":"7860_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","volume":"13","author":"S Rosengren","year":"2020","unstructured":"Rosengren S, Skibsted Clemmensen T, Tolbod L, Granstam SO, Eiskj\u00e6r H, Wikstr\u00f6m G, et al. Diagnostic accuracy of [11C]PiB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13:1337\u201347. https:\/\/doi.org\/10.1016\/j.jcmg.2020.02.023.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7860_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","volume":"27","author":"K Takasone","year":"2020","unstructured":"Takasone K, Katoh N, Takahashi Y, Abe R, Ezawa N, Yoshinaga T, et al. Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging. Amyloid. 2020;27:266\u201374. https:\/\/doi.org\/10.1080\/13506129.2020.1798223.","journal-title":"Amyloid"},{"key":"7860_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/RLU.0000000000003665","volume":"46","author":"X Wang","year":"2021","unstructured":"Wang X, Wang Y, Li J, Huo L, Zhang S. Noninvasive detection of cardiac amyloid with 11C-Pittsburgh compound B PET\/CT and 99mTc-PYP scintigraphy. Clin Nucl Med. 2021;46:776\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000003665.","journal-title":"Clin Nucl Med"},{"key":"7860_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.830572","volume":"9","author":"X Bi","year":"2022","unstructured":"Bi X, Xu B, Liu J, Wang G, An J, Zhang X, et al. Diagnostic value of 11C-PIB PET\/MR in cardiac amyloidosis. Front Cardiovasc Med. 2022;9:830572. https:\/\/doi.org\/10.3389\/fcvm.2022.830572.","journal-title":"Front Cardiovasc Med"},{"key":"7860_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/RLU.0000000000000492","volume":"39","author":"R Lhommel","year":"2014","unstructured":"Lhommel R, Sempoux C, Ivanoiu A, Michaux L, Gerber B. Is 18F-flutemetamol PET\/CT able to reveal cardiac amyloidosis? Clin Nucl Med. 2014;39:747\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000000492.","journal-title":"Clin Nucl Med"},{"key":"7860_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","volume":"33","author":"S Dietemann","year":"2019","unstructured":"Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography. Ann Nucl Med. 2019;33:624\u20138. https:\/\/doi.org\/10.1007\/s12149-019-01372-7.","journal-title":"Ann Nucl Med"},{"key":"7860_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","volume":"27","author":"S M\u00f6ckelind","year":"2020","unstructured":"M\u00f6ckelind S, Axelsson J, Pilebro B, Lindqvist P, Suhr OB, Sundstr\u00f6m T. Quantification of cardiac amyloid with [18F]flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid. 2020;27:191\u20139. https:\/\/doi.org\/10.1080\/13506129.2020.1760237.","journal-title":"Amyloid"},{"key":"7860_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","volume":"29","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M, Kessler L, Carpinteiro A, Hagenacker T, Nensa F, Umutlu L, et al. 18F-flutemetamol positron emission tomography in cardiac amyloidosis. J Nucl Cardiol. 2022;29:779\u201389. https:\/\/doi.org\/10.1007\/s12350-020-02363-2.","journal-title":"J Nucl Cardiol"},{"key":"7860_CR11","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652\u201362. https:\/\/doi.org\/10.1007\/s00259-014-2787-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7860_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","volume":"25","author":"R Manwani","year":"2018","unstructured":"Manwani R, Page J, Lane T, Burniston M, Skillen A, Lachmann HJ, et al. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid. 2018;25:247\u201352. https:\/\/doi.org\/10.1080\/13506129.2018.1552852.","journal-title":"Amyloid"},{"key":"7860_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jcmg.2024.05.002","volume":"17","author":"OF Clerc","year":"2024","unstructured":"Clerc OF, Datar Y, Cuddy SAM, Bianchi G, Taylor A, Benz DC, et al. Prognostic value of left ventricular 18F-florbetapir uptake in systemic light-chain amyloidosis. JACC Cardiovasc Imaging. 2024;17:911\u201322. https:\/\/doi.org\/10.1016\/j.jcmg.2024.05.002.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7860_CR14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","volume":"57","author":"WP Law","year":"2016","unstructured":"Law WP, Wang WYS, Moore PT, Mollee PN, Ng ACT. Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study. J Nucl Med. 2016;57:1733\u20139. https:\/\/doi.org\/10.2967\/jnumed.115.169870.","journal-title":"J Nucl Med"},{"key":"7860_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10741-025-10493-3","volume":"30","author":"A Aimo","year":"2025","unstructured":"Aimo A, Ferrari Chen YF, Castiglione V, Passino C, Genovesi D, Giorgetti A, et al. Positron emission tomography in cardiac amyloidosis: current evidence and future directions. Heart Fail Rev. 2025;30:605\u201318. https:\/\/doi.org\/10.1007\/s10741-025-10493-3.","journal-title":"Heart Fail Rev"},{"key":"7860_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.112.109009","volume":"54","author":"SM Landau","year":"2013","unstructured":"Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70\u20137. https:\/\/doi.org\/10.2967\/jnumed.112.109009.","journal-title":"J Nucl Med"},{"key":"7860_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:290\u2013300. https:\/\/doi.org\/10.1007\/s00259-013-2564-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7860_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","volume":"43","author":"K Adamczuk","year":"2016","unstructured":"Adamczuk K, Schaeverbeke J, Nelissen N, Neyens V, Vandenbulcke M, Goffin K, et al. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B. Eur J Nucl Med Mol Imaging. 2016;43(1):142\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3156-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7860_CR19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.nicl.2015.10.007","volume":"9","author":"JM Mountz","year":"2015","unstructured":"Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer\u2019s subjects. Neuroimage Clin. 2015;9:592\u20138. https:\/\/doi.org\/10.1016\/j.nicl.2015.10.007.","journal-title":"Neuroimage Clin"},{"issue":"12","key":"7860_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/MNM.0000000000001902","volume":"45","author":"B Zeydan","year":"2024","unstructured":"Zeydan B, Johnson DR, Schwarz CG, Przybelski SA, Lesnick TG, Senjem ML, et al. Visual assessments of 11 C-Pittsburgh compound-B PET vs. 18 F-flutemetamol PET across the age spectrum. Nucl Med Commun. 2024;45(12):1047\u201354. https:\/\/doi.org\/10.1097\/MNM.0000000000001902.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"7860_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","volume":"39","author":"VL Villemagne","year":"2012","unstructured":"Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O\u2019Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for A\u03b2 imaging in ageing and Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983\u20139. https:\/\/doi.org\/10.1007\/s00259-012-2088-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7860_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.112.114785","volume":"54","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880\u20136.","journal-title":"J Nucl Med"},{"key":"7860_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e1. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"key":"7860_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s12350-018-1349-x","volume":"27","author":"T Kero","year":"2020","unstructured":"Kero T, S\u00f6rensen J, Antoni G, Wilking H, Carlson K, Vedin O, et al. Quantification of 11C-PIB kinetics in cardiac amyloidosis. J Nucl Cardiol. 2020;27:774\u201384. https:\/\/doi.org\/10.1007\/s12350-018-1349-x.","journal-title":"J Nucl Cardiol"},{"key":"7860_CR25","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","volume":"64","author":"S Dorbala","year":"2023","unstructured":"Dorbala S, Kijewski MF. Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future. J Nucl Med. 2023;64:20S-S28. https:\/\/doi.org\/10.2967\/jnumed.122.264866.","journal-title":"J Nucl Med"},{"key":"7860_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11886-024-02114-6","volume":"26","author":"AJ Romero Pab\u00f3n","year":"2024","unstructured":"Romero Pab\u00f3n AJ, Clerc OF, Vijayakumar S, Cuddy SAM, Dorbala S. Recent advances in positron emission tomography radiotracers to image cardiac amyloidosis. Curr Cardiol Rep. 2024;26:1153\u201362.","journal-title":"Curr Cardiol Rep"},{"key":"7860_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2024.101816","volume":"33","author":"K Fujioka","year":"2024","unstructured":"Fujioka K, Norikane T, Takami Y, Yamamoto Y, Noma T, Nishiyama Y. Feasibility of PiB positron emission tomography\/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2024;33:101816. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.101816.","journal-title":"J Nucl Cardiol"},{"key":"7860_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","volume":"16","author":"JS Wall","year":"2023","unstructured":"Wall JS, Martin EB, Lands R, Ramchandren R, Stuckey A, Heidel RE, et al. Cardiac amyloid detection by PET\/CT imaging of iodine (124I) evuzamitide (124I\u2013p5+14): A Phase 1\/2 study. JACC Cardiovasc Imaging. 2023;16:1433\u201348. https:\/\/doi.org\/10.1016\/j.jcmg.2023.08.009.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7860_CR29","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","volume":"16","author":"OF Clerc","year":"2023","unstructured":"Clerc OF, Cuddy SAM, Robertson M, Vijayakumar S, Neri JC, Chemburkar V, et al. Cardiac amyloid quantification using 124I-Evuzamitide (124I-P5+14) versus 18F-Florbetapir: a pilot PET\/CT study. JACC Cardiovasc Imaging. 2023;16:1419\u201332. https:\/\/doi.org\/10.1016\/j.jcmg.2023.07.007.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7860_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2023.2286427","volume":"31","author":"R Lands","year":"2023","unstructured":"Lands R, Martin EB, Powell D, Stuckey A, Whittle B, Guthrie S, et al. Longitudinal PET\/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis. Amyloid. 2023;31:148\u20139. https:\/\/doi.org\/10.1080\/13506129.2023.2286427.","journal-title":"Amyloid"},{"key":"7860_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ph18091340","volume":"18","author":"TJ Hancock","year":"2025","unstructured":"Hancock TJ, Williams AD, Foster JS, Wall JS, Martin EB. Pan-amyloid reactive peptides p5+14 and p5R exhibit specific charge-dependent binding to glycosaminoglycans. Pharmaceuticals (Basel). 2025;18:1340. https:\/\/doi.org\/10.3390\/ph18091340.","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07860-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07860-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07860-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:11:55Z","timestamp":1779423115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07860-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7860"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07860-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Kagawa University Institutional Review Board (2023\u2013021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}